Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate

×

Overview

What is GaviLyte - N?

For oral solution: Each 4 liter (4L) GaviLyte-N jug contains a white powder for reconstitution. GaviLyte-N is a combination of polyethylene glycol 3350, an osmotic laxative, and electrolytes (sodium chloride, sodium bicarbonate and potassium chloride) for oral solution.

Each 4 liter jug contains: polyethylene glycol 3350 420g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.4 g. The solution is clear and colorless when reconstituted to a final volume of 4 liters with water.

Polyethylene Glycol 3350, NF

Sodium Bicarbonate, USP

The chemical name is NaHCO3. The average Molecular Weight is 84.01. The structural formula is:

Sodium Chloride, USP

The chemical name is NaCl. The average Molecular Weight: 58.44. The structural formula is:

Na+ Cl-

Potassium Chloride, USP

The chemical name is KCl. The average Molecular Weight: 74.55. The structural formula is:

K-Cl



What does GaviLyte - N look like?



What are the available doses of GaviLyte - N?

For oral solution:  One 4 liter jug with powder for reconstitution with water.

Each 4 liter jug contains: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 2 g. When made up to 4 liters volume with water, the solution contains PEG-3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

What should I talk to my health care provider before I take GaviLyte - N?

How should I use GaviLyte - N?

GaviLyte-N for oral solution is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy in adults and pediatric patients aged 6 months or greater ()

GaviLyte-N, supplied as a powder, must be reconstituted with water before its use; it is not for direct ingestion The 4 liter reconstituted GaviLyte-N solution contains: 420 grams of polyethylene glycol (PEG) 3350, 5.72 grams of sodium bicarbonate, 11.2 grams of sodium chloride, and 1.4 grams of potassium chloride. GaviLyte-N may be used with or without one of the supplied flavor packs.


What interacts with GaviLyte - N?

Sorry No Records found


What are the warnings of GaviLyte - N?

Sorry No Records found


What are the precautions of GaviLyte - N?

Sorry No Records found


What are the side effects of GaviLyte - N?

Sorry No records found


What should I look out for while using GaviLyte - N?

Gastrointestinal (GI) obstruction, ileus, or gastric retention (, )

Bowel perforation (, )

Toxic colitis or toxic megacolon ()

Known allergy or hypersensitivity to components of GaviLyte-N (, )


What might happen if I take too much GaviLyte - N?

Sorry No Records found


How should I store and handle GaviLyte - N?

In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19 In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19 In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19 In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19 In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19 In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19 In powdered form, for oral administration as a solution following reconstitution. GaviLyte-N is available in a disposable jug in powdered form containing:GaviLyte-N for oral solution with Flavor PacksLemon Flavor GaviLyte-NStorage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.Keep out of reach of children.GaviLyte-N with Flavor Packs NDC 43386-050-19


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.

Non-Clinical Toxicology
Gastrointestinal (GI) obstruction, ileus, or gastric retention (, )

Bowel perforation (, )

Toxic colitis or toxic megacolon ()

Known allergy or hypersensitivity to components of GaviLyte-N (, )

See . Misoprostol Tablets has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Misoprostol Tablets does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Misoprostol Tablets has no clinically significant effect on the kinetics of diclofenac or ibuprofen.

Prostaglandins such as Misoprostol Tablets may augment the activity of oxytocic agents, especially when given less than 4 hours prior to initiating oxytocin treatment. Concomitant use is not recommended.

Advise patients to hydrate adequately before, during, and after the use of GaviLyte-N. Use caution in patients with congestive heart failure when replacing fluids. If a patient develops significant vomiting or signs of dehydration including signs of orthostatic hypotension after taking GaviLyte-N, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN) and treat accordingly. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Fluid and electrolyte abnormalities should be corrected before treatment with GaviLyte-N.

In addition, use caution when prescribing GaviLyte-N for patients who have conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment []

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).